Clinical characteristics of EVI1+ patients in relation to clinical parameters, morphology, cytogenetics, and molecular characteristics of 534 patients with newly diagnosed AML
| . | No. of EVI1− patients . | No. of EVI1+ patients (%) . | P . |
|---|---|---|---|
| Sex* | .19 | ||
| Male | 242 | 25 (11) | — |
| Female | 251 | 16 (17) | — |
| Age, y* | .22 | ||
| Younger than 35 | 117 | 14 (11) | — |
| Between 35 and 50 | 166 | 12 (15) | — |
| Older than 50 | 210 | 15 (15) | — |
| HOVON protocol* | |||
| 04A | 49 | 3 (6) | >.99 |
| 04 | 40 | 8 (17) | .50 |
| 29 | 203 | 12 (6) | .32 |
| 32 | 5 | 0 (0) | >.99 |
| 42 | 140 | 11 (7) | .85 |
| 43 | 55 | 7 (11) | .54 |
| FAB* | |||
| M0 | 16 | 2 (11) | .64 |
| M1 | 104 | 6 (5) | .42 |
| M2 | 123 | 6 (5) | .18 |
| M3 | 24 | 1 (4) | .71 |
| M4 | 82 | 13 (14) | .11 |
| M5 | 104 | 10 (9) | .85 |
| M6 | 7 | 1 (12) | .47 |
| Mx | 33 | 2 (6) | >.99 |
| Cytogenetic abnormalities*† | |||
| −5/5q− | 16 | 3 (16) | .23 |
| −7/7q− | 21 | 13 (38) | <.001 |
| 3q26 | 2 | 8 (80) | <.001 |
| t(9;22)(q34;q11) | 1 | 1 (50) | .17 |
| t(11q23) | 8 | 8 (50) | <.001 |
| t(15;17)(q22;q21) | 21 | 1 (5) | .71 |
| t(8;21)(q22;q22) | 39 | 0 (0) | .039 |
| inv(16)/t(16;16) | 37 | 0 (0) | .065 |
| +8 | 22 | 2 (8) | .71 |
| +21 | 3 | 2 (40) | .05 |
| t(6;9)(p23;q34) | 6 | 0 (0) | >.99 |
| Complex | 20 | 1 (5) | >.99 |
| Other | 65 | 6 (8) | >.99 |
| Normal | 218 | 6 (3) | <.001 |
| ND | 20 | 2 (9) | >.99 |
| Cytogenetic risk* | |||
| Favorable | 89 | 1 (1) | .23 |
| Intermediate | 347 | 17 (5) | <.001 |
| Unfavorable | 57 | 23 (29) | <.001 |
| Molecular abnormalities* | |||
| FLT3 ITD | 135 | 5 (4) | .027 |
| FLT3 TKD | 43 | 1 (2) | .23 |
| KRAS | 5 | 0 (0) | >.99 |
| NRAS | 40 | 5 (11) | .57 |
| CEBPA | 43 | 1 (2) | .23 |
| NPM1 | 158 | 2 (1) | <.001 |
| WBC count, ×109/L,‡ mean; SD | 52; 63 | 45; 49 | .18 |
| Platelet count, ×109/L,‡ mean; SD | 72; 101 | 165; 241 | .01 |
| Blast % in BM,‡ mean; SD | 61; 27 | 61; 24 | .38 |
| . | No. of EVI1− patients . | No. of EVI1+ patients (%) . | P . |
|---|---|---|---|
| Sex* | .19 | ||
| Male | 242 | 25 (11) | — |
| Female | 251 | 16 (17) | — |
| Age, y* | .22 | ||
| Younger than 35 | 117 | 14 (11) | — |
| Between 35 and 50 | 166 | 12 (15) | — |
| Older than 50 | 210 | 15 (15) | — |
| HOVON protocol* | |||
| 04A | 49 | 3 (6) | >.99 |
| 04 | 40 | 8 (17) | .50 |
| 29 | 203 | 12 (6) | .32 |
| 32 | 5 | 0 (0) | >.99 |
| 42 | 140 | 11 (7) | .85 |
| 43 | 55 | 7 (11) | .54 |
| FAB* | |||
| M0 | 16 | 2 (11) | .64 |
| M1 | 104 | 6 (5) | .42 |
| M2 | 123 | 6 (5) | .18 |
| M3 | 24 | 1 (4) | .71 |
| M4 | 82 | 13 (14) | .11 |
| M5 | 104 | 10 (9) | .85 |
| M6 | 7 | 1 (12) | .47 |
| Mx | 33 | 2 (6) | >.99 |
| Cytogenetic abnormalities*† | |||
| −5/5q− | 16 | 3 (16) | .23 |
| −7/7q− | 21 | 13 (38) | <.001 |
| 3q26 | 2 | 8 (80) | <.001 |
| t(9;22)(q34;q11) | 1 | 1 (50) | .17 |
| t(11q23) | 8 | 8 (50) | <.001 |
| t(15;17)(q22;q21) | 21 | 1 (5) | .71 |
| t(8;21)(q22;q22) | 39 | 0 (0) | .039 |
| inv(16)/t(16;16) | 37 | 0 (0) | .065 |
| +8 | 22 | 2 (8) | .71 |
| +21 | 3 | 2 (40) | .05 |
| t(6;9)(p23;q34) | 6 | 0 (0) | >.99 |
| Complex | 20 | 1 (5) | >.99 |
| Other | 65 | 6 (8) | >.99 |
| Normal | 218 | 6 (3) | <.001 |
| ND | 20 | 2 (9) | >.99 |
| Cytogenetic risk* | |||
| Favorable | 89 | 1 (1) | .23 |
| Intermediate | 347 | 17 (5) | <.001 |
| Unfavorable | 57 | 23 (29) | <.001 |
| Molecular abnormalities* | |||
| FLT3 ITD | 135 | 5 (4) | .027 |
| FLT3 TKD | 43 | 1 (2) | .23 |
| KRAS | 5 | 0 (0) | >.99 |
| NRAS | 40 | 5 (11) | .57 |
| CEBPA | 43 | 1 (2) | .23 |
| NPM1 | 158 | 2 (1) | <.001 |
| WBC count, ×109/L,‡ mean; SD | 52; 63 | 45; 49 | .18 |
| Platelet count, ×109/L,‡ mean; SD | 72; 101 | 165; 241 | .01 |
| Blast % in BM,‡ mean; SD | 61; 27 | 61; 24 | .38 |
FAB indicates French-American-British classification; BM, bone marrow; FLT3 ITD, internal tandem duplication of the FLT3 gene; FLT3 TKD, a mutation in tyrosine kinase domain of the FLT3 gene; Mx, FAB not available; ND, not determined; —, not applicable; and SD, standard deviation.
P values were calculated using the 2-tailed chi-square test.
All patients with a specific abnormality were considered irrespective of the presence of additional abnormalities.
P values were calculated using 2-tailed t test.